Biogen Quarterly Balance Sheet
NASDAQ: BIIBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 230.50 +2.12%
Biogen financial position
As of Mar 31, 2026, Biogen reported total assets of $29.48 billion, up 5.2% from a year earlier against total liabilities of $10.83 billion. Shareholders' equity stood at $18.65 billion, or 63.3% of assets. The company held $3.38 billion in cash and equivalents against $6.29 billion of debt, a net debt position of $2.91 billion.
The current ratio (current assets divided by current liabilities) was 3.06, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.34.
Summary generated from market data by MetaCap's automated system. Methodology
Biogen balance sheet (quarterly)
| Quarter (USD) | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q2 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 3.38B | 3.01B | 3.86B | 2.76B | 2.60B | 2.38B | 1.70B | 1.91B | 1.07B | 1.05B | 2.29B | 2.62B |
| Short-Term Investments | 900.00M | 807.20M | 97.60M | — | — | 0 | — | — | — | 0 | 0 | 3.46B |
| Receivables | — | 1.34B | — | — | — | 1.40B | — | — | — | 1.66B | — | — |
| Inventory | 1.95B | 2.17B | 2.21B | 2.27B | 2.27B | 2.46B | 2.47B | 2.51B | 2.52B | 2.53B | 2.98B | 1.33B |
| Total Current Assets | 9.19B | 8.97B | 8.94B | 7.97B | 7.63B | 7.46B | 6.83B | 7.11B | 6.76B | 6.86B | 8.45B | 10.43B |
| Property, Plant & Equipment | 3.02B | 3.06B | 3.08B | 3.10B | 3.13B | 3.18B | 3.21B | 3.25B | 3.28B | 3.31B | 3.30B | 3.31B |
| Goodwill | 6.49B | 6.49B | 6.49B | 6.49B | 6.48B | 6.48B | 6.49B | 6.23B | 6.23B | 6.22B | 6.81B | 5.75B |
| Intangible Assets | 9.05B | 9.18B | 9.33B | 9.47B | 9.58B | 9.69B | 9.81B | 8.23B | 8.28B | 8.36B | 7.34B | 1.78B |
| Long-Term Investments | 465.60M | 431.90M | — | — | — | 0 | — | — | — | 0 | 100.00K | 1.21B |
| Total Assets | 29.48B | 29.44B | 29.21B | 28.33B | 28.03B | 28.05B | 28.31B | 26.80B | 26.57B | 26.84B | 28.19B | 25.16B |
| Accounts Payable | 358.50M | 432.00M | 413.10M | 408.40M | 391.50M | 424.20M | 422.70M | 354.50M | 387.00M | 403.30M | 440.10M | 445.40M |
| Short-Term Debt | — | 0 | — | — | — | 1.75B | — | — | — | 150.00M | — | — |
| Total Current Liabilities | 3.00B | 3.35B | 3.29B | 3.18B | 5.30B | 5.53B | 5.42B | 3.11B | 3.22B | 3.43B | 5.02B | 3.19B |
| Long-Term Debt | 6.29B | 6.29B | 6.29B | 6.28B | 4.55B | 4.55B | 4.55B | 6.29B | 6.29B | 6.79B | 6.79B | 6.28B |
| Total Liabilities | 10.83B | 11.18B | 11.00B | 10.70B | 11.05B | 11.33B | 11.95B | 10.91B | 11.35B | 12.05B | 13.71B | 10.70B |
| Shareholders' Equity | 18.65B | 18.26B | 18.21B | 17.63B | 16.98B | 16.72B | 16.36B | 15.89B | 15.21B | 14.80B | 14.48B | 14.47B |
| Retained Earnings | 20.87B | 20.55B | 20.60B | 20.14B | 19.50B | 19.26B | 18.99B | 18.60B | 18.02B | 17.63B | 17.38B | 17.45B |
| Total Debt | 6.29B | 6.29B | 6.29B | 6.28B | 4.55B | 6.30B | 4.55B | 6.29B | 6.29B | 6.94B | 6.79B | 6.28B |
| Net Cash (Debt) | -2.01B | -2.47B | -2.32B | -3.52B | -1.95B | -3.92B | -2.85B | -4.38B | -5.22B | -5.89B | -4.50B | -206.30M |
| Shares Outstanding | — | 146.80M | — | — | — | 145.80M | — | — | — | 144.90M | — | — |
This table shows 12 quarterly periods of Biogen's balance sheet, from Q1 2026 back to Q2 2023, across 20 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow BIIB's reporting calendar. What is a balance sheet?